A Multicentre Phase III Double-masked Randomised Controlled Non-Inferiority Trial comparing the clinical and cost effectiveness of intravitreal therapy with ranibizumab (Lucentis) vs aflibercept (Eylea) vs bevacizumab (Avastin) for Macular Oedema due to Central Retinal Vein Occlusion (CRVO)

Trial Profile

A Multicentre Phase III Double-masked Randomised Controlled Non-Inferiority Trial comparing the clinical and cost effectiveness of intravitreal therapy with ranibizumab (Lucentis) vs aflibercept (Eylea) vs bevacizumab (Avastin) for Macular Oedema due to Central Retinal Vein Occlusion (CRVO)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Jun 2016

At a glance

  • Drugs Aflibercept (Primary) ; Bevacizumab (Primary) ; Ranibizumab (Primary)
  • Indications Central retinal vein occlusion; Retinal oedema
  • Focus Therapeutic Use
  • Acronyms LEAVO
  • Most Recent Events

    • 05 Nov 2015 Accrual to date is 38% according to United Kingdom Clinical Research Network record.
    • 05 Nov 2015 Accrual to date is 31% according to United Kingdom Clinical Research Network record.
    • 05 Oct 2015 Accrual to date is 25% according to United Kingdom Clinical Research Network
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top